| Revision as of 08:21, 23 October 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified and watched fields - updated 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit | Revision as of 02:11, 11 January 2012 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs)Next edit → | ||
| Line 1: | Line 1: | ||
| {{Drugbox | {{Drugbox | ||
| | Verifiedfields = changed | | Verifiedfields = changed | ||
| ⚫ | | verifiedrevid = 470615098 | ||
| | Watchedfields = changed | |||
| ⚫ | | verifiedrevid = |
||
| | IUPAC_name = ''N''-{methyl}-<br>3,4,5-trimethoxy-benzamide | | IUPAC_name = ''N''-{methyl}-<br>3,4,5-trimethoxy-benzamide | ||
| | image = Trimethobenzamide.svg | | image = Trimethobenzamide.svg | ||
| Line 27: | Line 26: | ||
| | ATC_prefix = none | | ATC_prefix = none | ||
| | PubChem = 5577 | | PubChem = 5577 | ||
| | DrugBank_Ref = {{drugbankcite| |
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} | ||
| | DrugBank = APRD01277 | | DrugBank = APRD01277 | ||
| | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| Line 33: | Line 32: | ||
| | UNII_Ref = {{fdacite|correct|FDA}} | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| | UNII = W2X096QY97 | | UNII = W2X096QY97 | ||
| | ChEBI_Ref = {{ebicite| |
| ChEBI_Ref = {{ebicite|correct|EBI}} | ||
| | ChEBI = 27796 | | ChEBI = 27796 | ||
| | ChEMBL_Ref = {{ebicite|changed|EBI}} | | ChEMBL_Ref = {{ebicite|changed|EBI}} | ||
Revision as of 02:11, 11 January 2012
Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Trade names | Tigan |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682693 |
| Routes of administration | Oral, rectal, intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 7 to 9 hours (mean) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.004.848  |
| Chemical and physical data | |
| Formula | C21H28N2O5 |
| Molar mass | 388.458 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Trimethobenzamide (Tebamide, Tigan) is an antiemetic used to prevent nausea and vomiting. It is often prescribed for patients with gastroenteritis, medication-induced nausea, and other illnesses. Trimethobenzamide is generally considered the most potent antiemetic that does not have effects on the serotonergic, dopaminergic, or histaminergic systems, so it has a lower likelihood of causing undesired side effects. In the United States, it requires a prescription.
Mechanism of action
Although the specific mechanism through which trimethobenzamide functions is unknown, it is believed to affect the chemoreceptor trigger zone (CTZ) of the medulla oblongata.
Side effects
Possible side effects include drowsiness, dizziness, headache, diarrhea, muscle cramps, and blurred vision. More serious adverse effects include skin rash, tremors, parkinsonism, and jaundice.
Formulations
Trimethobenzamide is marketed under the brand names Tebamide and Tigan, manufactured by GlaxoSmithKline and King Pharmaceuticals, respectively. It is available as oral capsules and injectable formulations.
Trimethobenzamide was also available as a rectal suppository, but such formulations were banned by the U.S. Food and Drug Administration on April 6, 2007 due to unproven efficacy.
See also
References
- Waknine, Yael (April 6, 2007). "FDA Bans Suppositories With Trimethobenzamide". Medscape. Archived from the original on April 16, 2007. Retrieved 2007-04-06.
External links